Sensitivity as outcome measure of androgen replacement: the AMS scale
<p>Abstract</p> <p>Background</p> <p>The capacity of the AMS scale as clinical utility and as outcome measure still needs validation.</p> <p>Methods</p> <p>An open post-marketing study was performed by office-based physicians in Germany in 2004....
Main Authors: | Dinger Juergen C, Moore Claudia, Heinemann Lothar A, Stoehr Diana |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2006-03-01
|
Series: | Health and Quality of Life Outcomes |
Online Access: | http://www.hqlo.com/content/4/1/23 |
Similar Items
-
Quality of life and hormone use: new validation results of MRS scale
by: Heinemann Lothar AJ, et al.
Published: (2006-05-01) -
European active surveillance study of women taking HRT (EURAS-HRT): study protocol [NCT00214903]
by: Heinemann Lothar AJ, et al.
Published: (2006-01-01) -
The Aging Males' Symptoms (AMS) scale: review of its methodological characteristics
by: Moore Claudia, et al.
Published: (2003-12-01) -
ANDROGEN REPLACEMENT THERAPY IN POSTMENOPAUSE
by: Helena Meden Vrtovec
Published: (2008-12-01) -
Breast cancer risk associated with different HRT formulations: a register-based case-control study
by: Thai Do, et al.
Published: (2006-09-01)